Wonvog Trio 2 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.3mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, resulting in reduced postprandial hyperglycemia. The combined action of these three agents targets multiple pathophysiological defects of type 2 diabetes, offering improved glycemic control compared to monotherapy. Wonvog Trio 2 Tablet ER is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy with any of the individual components. The extended-release formulation allows for once-daily dosing, improving patient compliance. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and potential side effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This medication should be used under medical supervision with appropriate lifestyle modifications.